OBJECTIVE: Anemia is a common hematological disorder characterized by reduced hemoglobin concentrations. Despite information on prevalence and associated outcomes, little is known about the impact of anemia on health care utilization and costs. This study examines anemia prevalence and associated medical costs and utilization, using administrative claims for adults newly diagnosed with anemia, including up to 12 months of follow-up.
The National Health and Nutrition Examination Survey (NHANES) provides an assessment of anemia prevalence based on laboratory testing. Results from NHANES III show anemia to be most prevalent in children through age 16, women aged 17 to 49 years, and the elderly (aged 75 years and older), especially elderly men. 4 Anemia prevalence is higher among individuals with certain chronic conditions, including chronic kidney disease (CKD), human immunodeficiency virus (HIV), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), congestive heart failure (CHF), and cancer. 2, 5 In previous studies, anemia with chronic disease has been identified in 36% of patients with CKD 6 and 27% of patients with RA. 7 The increasing amount of information on the prevalence of anemia among individuals with such diseases supports the view that it is a condition of growing concern. [7] [8] [9] [10] [11] Anemia has been shown to be associated with increased mortality and morbidity as well as with decreased physical functioning and quality of life. 2, 12 Although anemia is often associated with disease progression or increased disease severity, evidence of its independent effect on these key outcomes is still accumulating.
Despite information on anemia prevalence and associated outcomes, little is known about the impact of anemia on health resource utilization and costs. Although the cost of anemia care has been examined using Medicare data for CKD, 13 cancer, 14, 15 and heart failure, 16 the literature provides no data on anemiarelated costs in other populations. Consequently, this study was undertaken to estimate the health care costs and treatment patterns of patients with anemia in a privately insured population.
ss Methods
This study is based on retrospective administrative claims data from commercially insured and Medicare plans represented in the Medstat MarketScan database, containing the combined administrative claims for more than 2 million health plan members for employers from across the country. The study population was selected only from those enrolled in plans with complete capture of facility-based and professional services, as well as outpatient prescription medications. The combined Medicare and commercial populations from which the study sample was drawn resided primarily in the southern, northern central, and northeastern regions of the United States, with a smaller representation from the western region.
Analyses were conducted to examine the prevalence of anemia and related utilization and health plan costs in an adult population. This paper presents results for the entire study population and separately for groups with specific conditions that are often associated with an increased occurrence of anemia or in which anemia presents particular clinical challenges. For condition-specific subgroup results, patients were identified based on the presence of diagnosis codes from the International Classification of Diseases, 9th Revision, Clinical Modification, (ICD-9-CM) for 6 conditions: CKD, HIV, RA, IBD, CHF, and solid-tumor cancer (Table 1) . Patients who had multiple diagnoses during the study period were included in all condition-specific groups for which they qualified.
Since laboratory values such as hemoglobin levels are not generally available in medical claims data, anemia was identified by the presence of at least 1 diagnosis code for anemia (occurring in any position on a claim), 1 procedure code (Current Procedural Terminology, 4th Edition [CPT-4], ICD-9-CM, or Health Care Financing Administration Common Procedure Coding System [HCPCS]), or 1 drug code indicative of anemia treatment (e.g., blood transfusions, injections with recombinant erythropoietin. Diagnoses used for patient selection include iron deficiency anemia, pernicious anemia, anemia of chronic disease, nutritional anemia, other specified aplastic anemias, and other unspecified anemia. Codes for acute anemias were not included, and blood transfusion was only considered in the absence of a diagnosis of acute anemia (ICD-9-CM 285.1) ( Table 2 ). The study was divided into 2 components. The first component assessed anemia prevalence in the year 2000. The denominator included all adult health plan members who had continuous
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Diagnosis Codes (ICD-9-CM) Used to Identify 6 Study Conditions Congestive heart failure Congestive heart failure 428.0 Malignant hypertensive heart disease (with congestive heart failure) 402.01 Benign hypertensive heart disease (with congestive heart failure) 402.11 Unspecified hypertensive heart disease (with congestive heart failure) 402.91 Malignant hypertensive heart and renal disease (with congestive heart failure) 404.01 Malignant hypertensive heart and renal disease (with congestive heart failure and renal failure) 404.03 Benign hypertensive heart and renal disease (with congestive heart failure) 404.11 Benign hypertensive heart and renal disease (with congestive heart failure and renal failure) 404.13 Unspecified hypertensive heart and renal disease (with congestive heart failure) 404.91 Unspecified hypertensive heart and renal disease (with congestive heart failure and renal failure) 404.93
Cancer (primary only)
Cancer diagnoses in the range of 140.0-199.x, excluding 173.0-173.9. For cancer patients, we required 2 outpatient diagnoses on separate service dates within 6 months or 1 diagnosis on an inpatient admission record.
ICD-9-CM = International Classification of Diseases, 9th
Revision, Clinical Modification; NOS = not otherwise specified.
medical and drug benefits coverage during 2000, and the numerator included all members with evidence of a specified anemia diagnosis or treatment. The second component used administrative claims for dates of service between January 1, 1998, and June 30, 2001, to compare the health care cost and utilization patterns between anemic and nonanemic patients within the 6 study conditions. We captured the sequence of anemia-related services in the year following the initial diagnosis. For the second part of the study, we selected only those patients who were "newly diagnosed" with anemia, defined as those with at least 1 year of continuous medical and drug benefits coverage prior to their anemia index date (date of first anemia diagnosis or procedure in the study period [ Table 2 ]) and no evidence of anemia diagnoses or treatment during this 1-year "history" period. For comparison, we selected patients who met the same health plan enrollment requirements as the anemic patients but had no evidence of anemia. We identified a comparison group for the overall anemic population and also constructed 6 condition-specific comparison groups using the same diagnostic criteria that we used for the anemic patients.
Since the objective of this study component was to characterize anemia care in the first year after diagnosis, follow-up data were examined for a maximum of 12 months after the anemia index date. Individual follow-up periods were determined by the amount of time that each patient had continuous benefits coverage following the anemia index date. To avoid skewing the study toward a sicker population, we did not require that patients remain in the health plan for the full 12 months of potential follow-up; this variable follow-up period was taken into consideration in the analyses.
For the cost model, we developed a variable to adjust for disease severity for each of the 6 conditions. Severity adjustment was based on specific ICD-9 codes, HCPCS codes for durable medical equipment, or pharmacy codes. Patients were separated into mild, moderate, and severe categories based on specific ICD-9 codes, HCPCS codes for durable medical equipment, or pharmacy codes. Cancer patients who were actively receiving chemotherapy were categorized as part of the moderate severity category, whereas those with evidence of metastasis were categorized as severe. CKD patients with 1 CKD hospitalization during follow-up were categorized as moderate while those with either more than 1 CKD hospitalization or with a kidney transplant were categorized as severe. Use of biologic therapies and selected nonbiologic therapies indicated moderate RA while joint surgery indicated severe RA. For IBD, more advanced medications, surgery, and multiple hospitalizations were indicators of severe disease. For CHF, the severity increased as the number of concomitant CHF medications and hospitalizations increased. The Charlson Comorbidity Index (CCI) was used to quantify burden of illness in the study population based on claims incurred during the 6 months before each patient' s index date. 17 In order to assess treatment patterns, we identified specific procedures and medications that are commonly used in the management of anemia. These included blood transfusions, erythropoietin injections, B12 injections, iron injections, and use of testosterone, nandrolone, folate, or folic acid. It is important to note that the study database captured information only on outpatient prescription medications and did not include utilization of any inpatient or over-the-counter medications. Anemia treatment regimens were assessed for up to 1 year following patients' anemia index dates; follow-up periods ended either at the conclusion of the study period or when patients left the health plan. All relevant therapies provided on or after the anemia index date were counted.
The costs evaluated in this study were the payments made by the health plan, after subtraction of member cost-share, as reported on the final adjudicated version of each claim. No adjustments were made to standardize costs across the study period. Unfortunately, the structure and level of detail of administrative claims precluded us from simply summing up payments in order to determine the cost of anemia. As is common in cost studies such as this one, we created an algorithm to estimate the direct health plan payments attributable to anemia. [14] [15] [16] For inpatient and outpatient (nonpharmacy) services, claims with either a primary or secondary diagnosis resulted in the attribution of a portion of the costs to anemia. In general, if anemia was listed as the primary diagnosis, 50% of the costs on the claim were attributed to anemia. If anemia was listed only as a secondary diagnosis, 25% of the costs were attributed to anemia.
Allocations for individual claims ranged from 0% to 100%, depending on whether the anemia diagnosis was primary or secondary, how many additional diagnoses were on the claims, and whether anemia-specific services (e.g., erythropoietin injection) appeared on the claim. In addition, costs for anemia-specific procedure codes were attributed to anemia even when anemia was not listed explicitly as a diagnosis (e.g., transfusion). For outpatient pharmacy claims, all erythropoietin costs were attributed to anemia.
Pairwise comparisons were performed for each variable according to the nature of the data involved: continuous variables were compared using t tests or nonparametric equivalents, and categorical variables were compared using chi-square tests. A multivariate analysis was also conducted to estimate cost 
ss Results
Based on data for the 2,296,832 adult health plan members with continuous benefits coverage during 2000, the overall anemia prevalence was 3.5% (81,423) ( Figure 1 ). Although statistical comparisons cannot be made because the condition groups were not mutually exclusive, it is clear that the prevalence of anemia varied significantly by condition, with CKD defining the upper end. Within each of the 6 study conditions, the relationship between anemia and age among females was not consistent. However, among males, anemia prevalence increased with age (Figures 2 and 3) . Overall, 118,332 anemic patients and a random sample of 35,948 nonanemic patients were identified for inclusion in the cost and utilization component of the study (Table 3) . (Case-matching was determined to be unnecessary in order to provide reasonably precise adjusted measures of association since the size of the study population was large). The number of patients in the condition-specific subgroups ranged from 354 anemic patients and 232 nonanemic patients in the HIV subgroup to 22,030 anemic patients and 17,542 nonanemic patients in the cancer subgroup (Table 3) . Females made up the majority of both the overall anemic and control populations (66% and 53%, respectively), and the proportion of females in the anemic population was statistically higher (P<0.001). With the exception of the HIV population, females were more common in the anemic populations for all study conditions (P < 0.01).
Overall, nonanemic patients were nearly 5 years older on average compared with the anemic patients (61.6 years vs. 56.9 years, P < 0.001). The opposite was true in the condition-specific populations: anemic patients were older, on average, than nonanemic patients in all of the condition-specific populations except for HIV (P < 0.002). With respect to the CCI, the overall population of anemic patients did not differ statistically from nonanemic comparison subjects (P = 0.22). However, in each of the 6 condition-specific populations, anemic patients had a statistically higher burden of illness as evidenced by higher CCI scores (P < 0.001). The difference in CCI scores was greatest in patients with CKD (1.6 for anemic vs. 0.98 for nonanemic) and those with cancer (1.6 for anemic and 0.56 for nonanemic).
Anemia Management
The average follow-up period for patients in this study was approximately 9 months.
Overall Population
In the overall population, the majority of anemic patients (86.5%) did not receive any of the therapies evaluated in this study (Figure 4) . Among therapies evaluated, transfusion was the most commonly used, with nearly 1 out of every 10 anemic patients (9.3%) receiving at least 1 blood transfusion during the follow-up period. These patients averaged 1.1 transfusions per month. For most transfused patients, transfusion was the only therapy used; approximately 1 in 5 also received erythropoietin, which was nearly always given after the transfusion. 
Condition-Specific Populations
As in the overall population, the majority of patients (85.2%-86.9%) in each of the 6 condition-specific populations had no documented anemia treatment. In these populations, the pattern of anemia treatment was similar to that in the overall population. Anemic HIV patients had the highest transfusion use (10.5% with at least 1 transfusion), but they also had the lowest average number of transfusions per patient per month (0.8). Therapy involving both transfusion and erythropoietin was most common among anemic HIV patients (27.0% of transfused patients) and least common among anemic RA patients (15.5% of transfused patients). Nearly 1 in 5 transfused CKD patients (19.1%) and cancer patients (19.2%) also received erythropoietin. Among condition-specific anemic populations, erythropoietin was used most commonly by HIV patients (4.5%) and least commonly by RA patients (2.8%). The majority of erythropoietin use in these populations was in conjunction with (usually following) blood transfusion.
Utilization and Costs
Utilization of selected key services was significantly higher for anemic patients (P < 0.001 in all cases), as presented in Table 4 . Similarly, per-patient payments for health care services (Tables  5 and 6 ) were higher for anemic patients than for nonanemic patients, both overall and within each of the 6 study conditions (P < 0.001). With the exception of outpatient pharmacy-based prescription drugs, anemic patients exhibited higher costs than did nonanemic patients for all types of care, including inpatient, outpatient, emergency room, and outpatient laboratory (P < 0.001). With the exception of outpatient facility care for HIV patients, this pattern of higher costs (including, in this case, higher outpatient prescription costs) among anemic patients persisted in the condition-specific populations (P < 0.03).
Among anemic patients, average total annualized costs were $14,535 per patient. Outpatient care, including physician office visits, accounted for more than half ($7,927, 54.5%) of the average total costs. Inpatient care accounted for nearly one third ($4,775, 33%) of the average total costs. Payments for pharmacybased outpatient prescriptions averaged $1,833. In the nonanemic population, average total annualized costs were $9,450 per patient. Outpatient care accounted for 45% ($4,262) of the total average costs, while inpatient care accounted for 36% ($3,375). Outpatient pharmacy payments averaged $1,813 (19%). Cost differences between anemic and nonanemic patients were statistically significant (P <0.001) for all types of care except outpatient pharmacy (P = 0.24). Table 7 presents adjusted and unadjusted differences in average annualized per-patient costs. Cost differences persisted after adjusting for differences in patient gender and age, coverage type (e.g., preferred provider organization, indemnity), predisposing condition (i.e., the 6 study conditions), and disease severity for each predisposing condition. The average annualized total cost per anemic patient was more than twice the average for nonanemic patients. Both outpatient and inpatient costs were more than twice as high for anemic patients as for nonanemic patients.
Services that we could attribute to anemia, based on our algorithm (i.e., claims for anemia treatment or claims containing a diagnosis of anemia), accounted for only 5% to 11% of the cost differential between anemic and nonanemic patients. Most of the difference was accounted for by services without an anemia diagnosis code or another unambiguous relationship to anemia. Average annualized anemia-attributed payments, using our algorithm, were $563 per patient. Outpatient care accounted for the largest share of anemia-attributed expenditures (which included a proportion of costs for services with either an anemia diagnosis or anemia-specific procedure such as erythropoietin administration), averaging $412 per patient annually (73% of total anemia-attributed costs). The costs of inpatient care attributable to anemia, based on our algorithm, were slightly lower than those for professionally administered outpatient medications, $90 and $99 per patient annually. Anemia-attributed outpatient prescription costs (i.e., costs for anemia-related medications) averaged $61 per patient annually.
Anemia Management Strategies by Condition

ss Discussion
For this study, we examined anemia prevalence, current treatment patterns, and associated costs of care in a privately insured population in order to determine the impact of anemia on the use of health care resources. In general, anemia occurred with noticeable frequency even in a relatively healthy privately insured population and resulted in higher health care utilization and costs. Overall, 3.5% of the study population was anemic at some point during the study year. It is somewhat challenging to compare this estimated anemia prevalence with estimates from previous studies, given that no standard definition of anemia is currently used and that reported and actual prevalence vary widely depending on the nature of the population studied. It is likely that the prevalence estimates of anemia in this study underestimate the true prevalence since, in order to be considered anemic, a patient was required to have a diagnosis of anemia recorded on a claim during the study period or to have received one of the specified anemia therapies.
These results underscore the fact that anemia is common enough to merit attention, even outside the context of those conditions with which it has historically been associated. Nearly 4% of the overall study population had anemia that was serious enough to be recorded as a diagnosis on a medical claim, to receive an anemia-related prescription medication, or to require an anemia-related procedure.
In general, these results highlight the importance of understanding the demographic and clinical risk factors that increase the likelihood that a particular individual will be anemic. From both public health and provider perspectives, such profiles of "at-risk" populations are critical for improving anemia screening, detection, and treatment. This study suggests that anemia merits particular attention in routine clinical care for women and the elderly.
Anemic patients used significantly more health care services and had higher costs ($14,535 vs. $9,451, P <0.001), even compared with patients with the same underlying condition who were not anemic. Since it is often assumed that anemia may simply be a marker for the severity of a key underlying disease (e.g., RA) and that disease severity would therefore be the primary driver for any observed cost differences, our multivariate analysis was designed to adjust for the presence of key conditions and the severity of those conditions as well as for other factors that could influence costs (i.e., patient age, gender, and coverage type). Our results indicate that costs of anemic patients were more than twice those of nonanemic patients even after adjusting for these other potential confounders. The majority of the anemic patients (85%) did not receive any of the therapies assessed. This is quite striking since these patients were primarily identified through the presence of explicit anemia diagnoses on the medical claims and, therefore, those with mild anemia may be underrepresented. One possible explanation is the use of oral iron, which was not captured in the study database because it is an over-the-counter medication. Nonetheless, the finding that only 15% of patients received any apparent treatment raises serious concern that anemia is inadequately managed. It is possible that physicians in general do not attribute much clinical importance to anemia, especially in patients who do not have medical conditions that may be exacerbated by anemia, and/or for whom anemia management is part of the standard of care. If that is the case, then efforts to increase awareness of anemia' s risk factors and consequences are needed, along with practical clinical treatment guidelines.
It may not be surprising that anemia in the overall health plan population appears to be either undertreated or minimally treated. It is surprising, however, that despite explicit guidelines These results also suggest that when anemia treatments are employed, their usage is remarkably similar across the 6 study conditions. The one exception is HIV, where the use of erythropoietin is more commonly observed than in the other conditions. This pattern suggests that the presence of underlying conditions may not play a significant role in clinical judgments about which anemia treatment is most appropriate or even about how aggressively to manage anemia.
Some of the observed treatment patterns also highlight specific quality-of-care considerations. Despite growing concern about the risks associated with transfusions and a wide array of initiatives to promote blood conservation, transfusions represented the predominant treatment among patients with newly diagnosed anemia in the study database. There is a clear gap between current practice relative to blood conservation and recommendations for transfusion alternatives. For example, current recommendations for use of blood products list iron, folate, B12, and erythropoietin therapy as specific therapies that should be administered instead of blood transfusions if the patient' s condition permits time for these agents to be utilized. 21 Since the current study focused only on use of injectable drugs, further analysis is necessary to understand the full extent to which these recommended first-line pharmaceutical therapies are used.
Limitations
Administrative claims data are one of the richest sources of information on health care utilization and cost and have historically served as the foundation for many areas of health services research. Like any data source, claims data present limitations: the most important is that the level of detail available is limited to that required for claims adjudication and internal and external health plan reporting. This limitation may lead to underidentification of anemia in the study population since the anemia diagnosis codes and anemia-related procedures and pharmaceutical therapies used for patient selection are only proxy indicators of anemia. The lack of actual hemoglobin levels for the patients in the study population also precludes the assessment of anemia severity. While claims data do present a reasonable amount of clinical information, no simple standard methodology was available to stratify patients by severity for the 6 study conditions. Finally, although the costs presented in this paper may differ from those experienced by another health plan due to differing fee schedules, the more critical finding is the statistically higher health care costs associated with anemia.
Although the data collected are not sufficient to explain why health care costs are higher among anemic patients, we would like to suggest a few possible explanations. First, despite our best efforts to control for disease severity and comorbidity burden in this analysis, it is possible that anemic patients are simply sicker than the controls and therefore use more health care services. It is also possible that the presence of anemia may contribute to a higher rate of detection of comorbidities in these patients or that anemic patients with comorbidities may be more likely to have their anemia detected, resulting in an association that is not causal.
These adjusted cost comparisons should also be considered in light of our examination of anemia-attributed costs (e.g., costs due to specific anemia visits, tests, and therapies). Although these anemia-attributed costs certainly contributed to overall health care costs in the study population, they represented only a small percentage of the total costs per patient. These results suggest that anemia may be responsible for excess costs in areas that cannot be captured by our algorithm or, alternatively, that the association is a marker for disease severity associated with increased costs (i.e., that the association is not causal).
ss Conclusions
The results of this study demonstrate that the elevated clinical burden that anemia imposes at the patient level in turn increases the resource burden at the health plan level. As anemia gains greater recognition as both an important clinical and public health issue, careful consideration should be given to determining the most cost-effective approaches to anemia screening in highrisk populations and efforts to improve anemia diagnosis and treatment. Given the challenges inherent in isolating the true costs of anemia, future research should examine the economic impact of more aggressive anemia treatment to determine if expected short-term cost increases incurred by earlier treatment would be offset by savings from fewer admissions, shorter lengths of stay, and less use of other expensive services in the treatment of anemia-related outcomes. Target research should also examine the extent to which patient care is consistent with current guidelines.
